Literature DB >> 16286387

The effect of corticosteroid medication on quantitative MR parameters of the brain.

Stefan C A Steens1, Gerda M Steup-Beekman, Gerlof P Th Bosma, Faiza Admiraal-Behloul, Hans Olofsen, Joost Doornbos, Tom W J Huizinga, Mark A van Buchem.   

Abstract

BACKGROUND AND
PURPOSE: Quantitative MR imaging techniques such as magnetization transfer imaging (MTI), diffusion-weighted imaging (DWI), and MR spectroscopy are promising diagnostic tools for use with patients with diffuse brain diseases such as neuropsychiatric systemic lupus erythematosus (NPSLE). Such patients are often on corticosteroid (CS) treatment. Presently, it is unknown whether CSs per se influence quantitative MR imaging measurements. The aim of this study was to evaluate the effect of low-dose oral CSs on MTI, DWI, and MR spectroscopy parameters of the brain.
METHODS: Twenty-seven rheumatoid arthritis (RA) patients with and without CS medication and 15 healthy controls were subjected to conventional MR imaging, whole-brain MTI and DWI, and single-voxel MR spectroscopy. Oral CSs were used by 13 of the RA patients. Univariate analyses with age as a covariate were performed on MTI, DWI, and MR spectroscopy parameters between RA patients with and without CSs and healthy controls. Pearson correlations were calculated between all imaging parameters and duration of disease, duration of CS use, and CS dosage.
RESULTS: No significant differences between the groups of subjects or significant correlations with clinical parameters were found for MTI, DWI and MR spectroscopy parameters.
CONCLUSION: In this study, we found no evidence for an effect of low-dose oral CSs on whole-brain MTI and DWI histogram parameters and single-voxel MR spectroscopy measurements of the brain. The results of this study demonstrate that it is unlikely that MTI, DWI, and MR spectroscopy parameters reported in NPSLE studies are confounded by low-dose oral CS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286387      PMCID: PMC7976209     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  32 in total

1.  Automated image registration: II. Intersubject validation of linear and nonlinear models.

Authors:  R P Woods; S T Grafton; J D Watson; N L Sicotte; J C Mazziotta
Journal:  J Comput Assist Tomogr       Date:  1998 Jan-Feb       Impact factor: 1.826

2.  Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging.

Authors:  G P Bosma; M J Rood; A H Zwinderman; T W Huizinga; M A van Buchem
Journal:  Arthritis Rheum       Date:  2000-01

3.  Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging.

Authors:  G P Bosma; M J Rood; T W Huizinga; B A de Jong; E L Bollen; M A van Buchem
Journal:  Arthritis Rheum       Date:  2000-11

Review 4.  Imaging modalities in central nervous system systemic lupus erythematosus.

Authors:  T W Huizinga; S C Steens; M A van Buchem
Journal:  Curr Opin Rheumatol       Date:  2001-09       Impact factor: 5.006

Review 5.  Intravenous pulses of methylprednisolone for systemic lupus erythematosus.

Authors:  Humeira Badsha; Christopher J Edwards
Journal:  Semin Arthritis Rheum       Date:  2003-06       Impact factor: 5.532

6.  Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.

Authors:  A B Rao; N Richert; T Howard; B K Lewis; C N Bash; H F McFarland; J A Frank
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

7.  Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus.

Authors:  G P Th Bosma; S C A Steens; Helen Petropoulos; Faiza Admiraal-Behloul; A van den Haak; J Doornbos; T W J Huizinga; William M Brooks; Aaron Harville; Wilmer L Sibbitt; M A van Buchem
Journal:  Arthritis Rheum       Date:  2004-10

8.  Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy.

Authors:  W L Sibbitt; L J Haseler; R H Griffey; B L Hart; R R Sibbitt; N A Matwiyoff
Journal:  AJNR Am J Neuroradiol       Date:  1994-05       Impact factor: 3.825

9.  Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy.

Authors:  E Sherwood Brown; Dixie J Woolston; Alan Frol; Leonardo Bobadilla; David A Khan; Margaret Hanczyc; A John Rush; James Fleckenstein; Evelyn Babcock; C Munro Cullum
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382

10.  Cerebral atrophy in systemic lupus erythematosus: steroid- or disease-induced phenomenon?

Authors:  S G Ostrov; R M Quencer; N B Gaylis; R D Altman
Journal:  AJNR Am J Neuroradiol       Date:  1982 Jan-Feb       Impact factor: 3.825

View more
  4 in total

1.  Diffusion tensor imaging analysis of rheumatoid arthritis patients with neuropsychiatric features to determine the alteration of white matter integrity due to vascular events.

Authors:  Pranjal Phukan; Bhupen Barman; Nivedita Kharkongor Chengappa; Donboklang Lynser; Subhraneel Paul; Arvind Nune; Kalyan Sarma
Journal:  Clin Rheumatol       Date:  2022-06-25       Impact factor: 3.650

2.  Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; William M Brooks; Mario Kornfeld; Blaine L Hart; Arthur D Bankhurst; Carlos A Roldan
Journal:  Semin Arthritis Rheum       Date:  2009-10-31       Impact factor: 5.532

3.  Selective involvement of the amygdala in systemic lupus erythematosus.

Authors:  Bart J Emmer; Jeroen van der Grond; Gerda M Steup-Beekman; Tom W J Huizinga; Mark A van Buchem
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

Review 4.  New insights into the impact of neuro-inflammation in rheumatoid arthritis.

Authors:  Nicholas R Fuggle; Franklyn A Howe; Rachel L Allen; Nidhi Sofat
Journal:  Front Neurosci       Date:  2014-11-06       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.